Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

48.41 +0.57 (+1.19%)
Official Closing Price Updated: 7:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Bristol-Myers Squibb

< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
56 57 Next >
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Dirt Cheap Dividend Stock to Buy in May
Don't wait too long before getting in on this excellent drugmaker. 
Via The Motley Fool
The FTC, Amgen, And Horizon: A New Hurdle For Biotech Deal Making Or Regulatory Overreach?
The FTC suit against Amgen appears to be a clear case of regulatory overreach but what this ultimately means will take time to fully develop. 
Via Talk Markets
Looking Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
Is Bristol-Myers Squibb Stock a Buy Now?
The stock faces risks, but are they outweighed by its low valuation? 
Via The Motley Fool
Should Income Investors Buy This Blue Chip Dividend Stock?
This pharmaceutical company has an exceptional drug portfolio and pipeline. 
Via The Motley Fool
Pfizer CEO Fires Back On US Drug Pricing Reforms: 'Negotiation with a Gun to Your Head'
Pfizer Inc's (NYSE: PFE) CEO Albert Bourla called U.S. plans to negotiate drug prices for its Medicare health program "negotiation with a gun to your head."  
Via Benzinga
3 High-Yielding Dividend Stocks That Could Pay You Forever
These are stocks that you can buy and forget about. 
Via The Motley Fool
3 Things About Bristol-Myers Squibb That Smart Investors Know
Its medium-term performance is going to rest on the acquisitions it makes today. 
Via The Motley Fool
$100,000 Salaries No Longer Enough — Majority Living Paycheck To Paycheck With No Savings
Via Benzinga
Which Is the Better Passive Income Stock, Eli Lilly or Bristol Myers Squibb?
One offers more income today, and the other aims to offer more in the future. 
Via The Motley Fool
Insiders Selling Zoom Video Communications, Bristol-Myers Squibb And This Footwear Manufacturer
The Nasdaq closed lower on Thursday after the Fed increased rates by 25 basis points on Wednesday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
Bristol-Myers Squibb Earnings Perspective: Return On Capital Employed
Via Benzinga
Bristol-Myers Squibb Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
7 Best Dividend Stocks to Buy Now in May 2023
These top dividend stocks are attractive at these levels and lower, and they add excellent diversity to a long-term investing portfolio. 
Via The Motley Fool
Want Passive Income at a Fair Price? Consider Buying This Dividend Growth Stock
It's in the sweet spot for the right kind of investor. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration
Bristol-Myers Squibb Co (NYSE: BMY) announced  
Via Benzinga
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
Microsoft, Meta, Cloudflare and Crocs were among the many big movers. 
Via Investor's Business Daily
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Bristol Myers Squibb Posts Lower Q1 Sales As Revlimid Generic Erosion Bites, Chairman & CEO Giovanni Caforio To Step Down
Via Benzinga
A New Depression Drug Being Developed By Tonix May Side-Step Treatment-Limiting Effects Of Nearly All Current Antidepressants In The US
The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The sponsored content team works to ensure... 
Via Benzinga
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher. 
Via Benzinga
LianBio Touts Positive Data From Bristol Myers-Partnered Heart Drug In Chinese Patients
LianBio (NASDAQ: LIAN) announced  
Via Benzinga
Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market – Interim Results Could Be Released In Second Half Of 2023
Recently, Allarity Therapeutics, Inc. (NASDAQ: ALLR) announced plans to speed up its Phase 2 clinical trial for IXEMPRA®, the clini 
Via Benzinga
This Supercharged Dividend King Stock Might Soon Run Out of Steam
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025. 
Via The Motley Fool
< Previous 1 2
...
26 27 28 29 30 31 32 33 34
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.